Actively Recruiting
Study of Empagliflozin Effects on Muscle Energy Use and Heart Function in Adults with Type 2 Diabetes and Heart Failure
Led by The University of Texas Health Science Center at San Antonio · Updated on 2026-04-06
30
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the effects of SGLT2 inhibitors, specifically empagliflozin, on people with type 2 diabetes and heart failure with reduced ejection fraction. The study aims to understand how increased plasma ketones from this medication impact skeletal muscle and heart muscle ketone uptake, muscle energy production, exercise capacity, and patient-reported physical function and well-being. Participants will be randomly assigned to one of two groups one receiving empagliflozin 25 mg orally once daily for 12 weeks, and the other receiving a placebo for the same duration. The study uses detailed muscle and heart imaging techniques to measure energy metabolites and exercise capacity, alongside questionnaires assessing physical function. During the study, participants will undergo muscle bioenergetic assessments using specialized magnetic resonance spectroscopy, cardiopulmonary function tests, and patient-reported outcome surveys. Researchers will measure changes in muscle energy compounds and exercise capacity over the 3-month treatment period to evaluate how empagliflozin affects heart and muscle function in this population.
CONDITIONS
Brief Title
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Research Team
C
Carolina Solis-Herrera, MD
F
Francisca M Acosta, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
